Our study demonstrates the therapeutic potential of AEOL as a modulator of the NRF2–DWORF pathway, ultimately leading to preserved cardiac contractility, reduced myocardial injury, and protection against HF development. The gene discussed is NFE2L2; the disease is hydrops fetalis.